Omeros (OMER) Operating Income (2010 - 2026)
Omeros (OMER) posted Operating Income of -$17.4 million for Q1 2026, up 40.09% sequentially from -$29.1 million in Q4 2025, and up 50.18% YoY from -$11.6 million in Q1 2025.
Omeros (OMER) Operating Income (2010 - 2026) Analysis & Trends
Omeros has reported Operating Income for 17 years, with the latest figure at -$17.4 million in Q1 2026.
- Quarterly Operating Income rose 50.18% year-over-year to -$17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105.2 million (up 35.39% YoY) and the FY2025 annual result came in at -$122.8 million, up 26.45% from the prior year.
- Operating Income grew to -$17.4 million in Q1 2026 per OMER's latest filing, from -$29.1 million in the prior quarter.
- Over five years, Operating Income peaked at -$17.4 million in Q1 2026 and troughed at -$59.2 million in Q2 2024.
- A 5-year average of -$37.4 million and a median of -$35.7 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2026: Operating Income sank 44.64% in 2024, then soared 50.18% in 2026.
- Over 5 years, Operating Income stood at -$40.1 million in 2022, then gained by 0.93% to -$39.8 million in 2023, then grew by 16.12% to -$33.4 million in 2024, then advanced by 12.81% to -$29.1 million in 2025, then surged by 40.09% to -$17.4 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$17.4 million, -$29.1 million, and -$26.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 74,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74,000.00 |
| Mar 31, 2026 | -17.42 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -26.39 Mn |
| Jun 30, 2025 | -32.35 Mn |
| Mar 31, 2025 | -34.97 Mn |
| Dec 31, 2024 | -33.36 Mn |
| Sep 30, 2024 | -35.41 Mn |
| Jun 30, 2024 | -59.16 Mn |
| Mar 31, 2024 | -39.03 Mn |
| Dec 31, 2023 | -39.77 Mn |
| Sep 30, 2023 | -48.15 Mn |
| Jun 30, 2023 | -40.90 Mn |
| Mar 31, 2023 | -35.71 Mn |
| Dec 31, 2022 | -40.14 Mn |
| Sep 30, 2022 | -50.77 Mn |
| Jun 30, 2022 | -37.44 Mn |
| Mar 31, 2022 | -35.05 Mn |
| Dec 31, 2021 | -42.89 Mn |
| Sep 30, 2021 | -39.83 Mn |